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ABSTRACT
In Hong Kong, universal varicella vaccination was introduced in July 2014 with a two-dose schedule but
the vaccines had been available in the private market since 1996. With data from varicella notification
and surveys on immunization coverage, we used the screening method to estimate dose-specific
varicella vaccine effectiveness (VE) among preschool children in Hong Kong before universal vaccination.
We estimated the VE of one- and two-dose varicella vaccination against all notified varicella as 69.4%
(95% confidence interval (95% CI) 69.5–71.2) and 93.4% (95% CI 91.7–94.7), respectively. We found that
VE did not decrease with time since receipt. Varicella vaccine was more effective against complications
(85.4% [95% CI 48.8–95.8] for one dose and 100% [95% CI –Inf to 100] for two doses) and against
hospital admission (75.2% [95% CI 53.4–86.8] for one dose and 93.1% [95% CI 47.1–99.1] for two doses).
Lower protection of one-dose varicella vaccine resulted in breakthrough varicella. Under universal
vaccination, second-dose varicella vaccine (given as combined measles, mumps, rubella and varicella
vaccine) was first scheduled for children when they reach primary one (about 6 years of age) and was
recently advanced to 18 months of age. Shortening the interval between the first dose and second dose
of varicella vaccination should reduce breakthrough varicella and outbreaks in preschool.
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Introduction
Universal varicella vaccination (UVV) in Hong Kong was intro-
duced in July 2014 for children born in 2013 and after with a two-
dose schedule at 12 months and around 6 years of age (at the start
of primary school).1 Monovalent varicella vaccine (mVV) is pro-
vided as the first dose whilst combined measles, mumps, rubella,
and varicella (MMRV) is provided as the second dose. However,
before the start of UVV, varicella vaccine was licensed for private
market use in 1996 with no clear schedule and the first dose
vaccination uptake gradually reached up to 50% among preschool
children.2 The private market was dominated bymVV fromGSK,
Sanofi, and MSD (Table 1). All three products consisted of live
attenuated varicella virus (Oka strain) with at least 1350 plaque-
forming unit.3 We found that most vaccinated preschool children
only received one dose of vaccine, with median age of vaccination
ranging from about 15 to 20 months of age.2 We previously
reported the burden of varicella shifting to older children during
the period of increasing vaccination uptake in the private market.
However, the extent to which this increase in varicella vaccination
contributed to the change in epidemiology remains uncertain.2
Vaccinees developing modified (less severe) varicella is often
referred to as breakthrough infections.3 In the United States, the
frequent reporting of breakthrough infections in one-dose reci-
pients with low protection against varicella4,5 has led to the
implementation of two-dose program, with the first dose sched-
uled at 12–15 months while the second dose was scheduled at 4–
6 years. Yet, in Hong Kong, the second dose was first scheduled
at about 6 years of age and hence at least 5 years following the
first dose of varicella vaccine. The decision to space out the two
doses was largely on programmatic grounds and this schedule
may result in a high number of breakthrough cases before receipt
of a second dose because of limited effectiveness6 or potential
waning following a single dose of varicella vaccine.
We used the screening method to estimate the direct effect
of varicella vaccine in Hong Kong before UVV. The primary
objective of this study is to estimate the effectiveness of
varicella vaccine against varicella infections of all severity in
preschool children in Hong Kong. Secondary objectives
include estimating varicella vaccine dose-specific effectiveness,
whether vaccine effectiveness (VE) waned with time and VE
against complications and severe diseases.
Patients and methods
We used the screening method7,8 to estimate the effectiveness
of varicella vaccine among children aged 3–5 years in
Hong Kong. In contrast to vaccine efficacy, which is typically
defined as the direct effect of a vaccine measured in pre-
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licensure clinical trials, VE commonly referred to the esti-
mated protection attributed to a vaccine under post-
licensure, field conditions.9 Post-licensure VE is commonly
estimated using case–control and cohort studies by comparing
the attack rate or incidence rate among vaccinated and unvac-
cinated cases. On the other hand, the screening method is
used to estimate VE by making use of surveillance data con-
sisting of the vaccination coverage among the cases and the
source population.7,8 In our study, we compared the propor-
tion of childhood varicella cases who were vaccinated (PCV)
with the proportion of the children vaccinated in the source
population (PPV) for the corresponding age cohort to obtain
the VE.
Data sources
PPVwas obtained from territory-wide immunization surveys on
preschool children conducted by the Department of Health
(DH). The surveys were cross-sectional studies using stratified
cluster sampling of preschools in Hong Kong to estimate vaccine
uptake, which was the proportion of children receiving
a particular vaccine. Vaccination status was ascertained by
reviewing documented vaccination records. As the screening
method is disproportionately prone to error when the PPV
and PCV is very high or very low,7 we chose surveys conducted
in 2009, 2012, and 2015 covering cohorts with an intermediate
uptake of 23.8–51.0% in the private market. This provided us
with additional confidence for a robust VE estimation before
UVV as first dose uptake for children eligible for universal
vaccination has reached 99%.10 About 5% of preschools were
selected in these three surveys, with 6051–8522 children aged
2–5 from sampled preschools were recruited in these three
surveys. We used varicella vaccine uptake of children aged 3–5
only as preschool attendance rate for children of these ages were
high,11 compared to the 50% attendance rate for those aged 2
years. Details of the surveys have been reported elsewhere.2
Survey data readily available for analysis included demographics
(including birth year, sex, place of birth, and residence) and
varicella vaccination history (including vaccination status, num-
ber of dose(s) received, and date of vaccination (for 2015)). Two
independent reviewers retrospectively digitalized the number of
dose(s), date of vaccination, and vaccine product for the 2009
and 2012 surveys from stored paper forms. We described the
varicella vaccination uptake for different birth cohorts, including
the number and proportion of surveyed children that received
varicella vaccine, as well as the timeliness of vaccination, as
indicated by median and interquartile range of the age of
vaccination.
Varicella is a notifiable disease inHong Kong. TheDH receives
varicella notifications from doctors in public and private sectors,
as well as from varicella outbreaks from schools and institutions.
Probable cases were defined as those with the clinical presentation
of acute onset of diffuse (generalized) papulovesicular rash with-
out other apparent cause or atypical (milder) clinical presentation
for those with varicella vaccination history. Confirmed cases were
defined as probable cases with either laboratory confirmation or
epidemiologically linked to a confirmed case. We included all
confirmed and probable cases in our analyses. Parents and/or
doctors were interviewed using a standard questionnaire to obtain
the demographics (including age, gender, place of residence, and
travel history during the incubation period), clinical information
(including date of onset, any varicella-related complications, hos-
pitalization, and fatality), and varicella vaccination history (vacci-
nation status, number of dose(s) received, and age of last varicella
vaccination). Number of dose(s) was recorded for cases reported
in 2012 onwards. However, since second-dose varicella vaccina-
tion uptake for children surveyed in 2009 was only 0.5% or below
(Table 2) and the information on number of dose(s) was not
collected for varicella cases reported in 2009, we assumed that all
vaccinated varicella cases in 2009 received only one dose. Doctors
and/or hospitals were contacted to obtain clinical information
when parents reported that their children developing varicella-
related complications and/or were admitted to hospitals. We
extracted information from the questionnaire into an electronic
database. To match with the children captured by the immuniza-
tion surveys (source population), we selected reported cases aged
3–5 years attending preschools in 2009, 2012, and 2015. We
excluded cases who did not attend preschools, who did not reside
in Hong Kong or imported cases (i.e. those who had a travel
history during the incubation period), or who resided in residen-
tial homes from our analyses as these children were unlikely to be
sampled in the immunization surveys. Children fulfilling one of
the following criteria were regarded as attending preschools:
attendance being confirmed by parents, notifications by pre-
schools, or cases identified during investigation of varicella out-
breaks in preschools. We described the demographics of varicella
cases included in our analysis.
Assessing waning immunity
To assess whether the effectiveness of varicella vaccine waned
with time, time since last vaccination was computed for vacci-
nated cases by subtracting the age at most recent varicella vacci-
nation by the age at disease onset. Waning refers to the loss of
vaccine protection with time. Similar computation is needed for
unvaccinated cases when VE is estimated by the screening
method.12,13 Studies carried out when a common vaccination
schedule was in place could impute the time of vaccination by
assuming that unvaccinated cases would have received the vac-
cine under the recommended schedule.12,13 In our study,
Table 1. Type of varicella vaccine received for vaccinated survey participants,
2009 and 2012 immunization survey for preschool children, Hong Kong.
First dose Second dose
2009 2012 2009 2012
Type of varicella vaccine N % N % N % N %
mVV Varilix (GSK) 496 32.7 658 39.7 12 54.5 13 19.7
Okavax (Sanofi) 195 12.8 171 10.3 0 0.0 8 12.1
Varivax (MSD) 68 4.5 118 7.1 3 13.6 5 7.6
Manufacturers
from mainland
China
14 0.9 13 0.8 0 0.0 0 0.0
GreenCross Korea 0 0.0 1 0.1 0 0.0 0 0.0
MMRV PriorixTetra (GSK) 0 0.0 0 0.0 0 0.0 4 6.1
Exact brand and
manufacturer
unclear
0 0.0 0 0.0 0 0.0 3 4.5
Unknown 746 49.1 695 42.0 7 31.8 33 50.0
Total 1519 100.0 1656 100.0 22 100.0 66 100.0
mVV: monovalent varicella vaccine
MMRV: combined measles, mumps, rubella and varicella vaccine
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varicella VE was estimated before universal vaccination and the
age of vaccination through private market in the source popula-
tion was highly diverse (Table 2). Therefore, the time since last
(hypothetical) vaccination for unvaccinated cases cannot be
approximated by simply using the recommended age of vaccina-
tion or the median age of vaccination in the healthy population.
Assuming the time of vaccination for unvaccinated cases would
have been comparable to those in the population should they
choose to vaccinate, we imputed the age of (hypothetical) vacci-
nation for unvaccinated cases from the observed vaccination
timing in the population, i.e. survey respondents vaccinated
against varicella (Supplementary Figure 1). In order to obtain
a dataset with the age of (hypothetical) vaccination for unvacci-
nated cases completely imputed, we first imputed missing values
of vaccination-related variables among vaccination survey
respondents and varicella cases to obtain complete datasets.
The imputation process is described in detail in Supplementary
Figure 1. A maximum number of 25 iterations for each imputa-
tion was chosen as 20–30 iterations were suggested to be suffi-
cient in achieving convergence of variables under imputation,
which is fewer than other Gibbs sampling methods.14 We cre-
ated 500 multiply imputed datasets.
Estimation of VE
Following Orenstein,7 we estimated VE via:
VE ¼ 1 PCVð Þ 1 PPVð Þ= 1 PCVð Þ PPVð Þ½ 
We computed PPV specific to different years (2009, 2012, and
2015), age (3, 4, and 5 years), and dose (at least one, one and
two doses). PPV were then matched to each varicella cases
based on their year of survey/notification, age, and number of
dose(s) received. We computed the VE following the
approach suggested by Farrington,15 which was also adopted
and described in detail in other VE studies:12,16,17
In P= 1 Pð Þ½  ¼ c þ In PPV= 1 PPVð Þ½ 
where P is the probability of vaccination status of reported cases
fitted as a binary outcome (vaccinated or not), with log odds of
the matched PPV (In[PPV/(1-PPV)]) as an offset in a logistic
regression model. VE was obtained as VE = 1 – exp(c) where
c was the estimated constant in the regression model.
VE estimates were obtained for each imputed dataset and
then pooled to give a single estimate for which the within- and
between-imputation variance was accounted for according to
Table 2. Varicella vaccination uptake and age of vaccination in preschool children surveyed and preschool children with varicella reported in Hong Kong, 2009, 2012,
and 2015.
Varicella vaccination among preschool children surveyed
At least 1 dose 1st dose 2nd dose
Survey year
Age
(years)/
cohort
Number
surveyed
Number
received (%)
Number
received (%)
Median age (months) at 1st
dose (IQR)
Number
received (%)
Median age (months) at 2nd
dose (IQR)
2009 5/2003 1666 397 (23.8) 375 (22.5) 25.5 (16.7–34.5) 7 (0.4) 40.0 (38.7–64.1)
4/2004 1726 509 (29.5) 405 (23.5) 24.9 (16.5–32.4) 9 (0.5) 40.7 (35.9–49.7)
3/2005 1819 613 (33.7) 526 (28.9) 23.0 (15.6–28.8) 6 (0.3) 37.0 (35.2–37.4)
2012 5/2006 1596 430 (26.9) 375 (23.5) 20.6 (14.7–29.5) 24 (1.5) 62.0 (39.3–65.5)
4/2007 1834 614 (33.5) 546 (29.8) 19.0 (14.2–27.9) 22 (1.2) 48.7 (36.6–51.7)
3/2008 1815 612 (33.7) 575 (31.7) 18.4 (14.1–25.9) 20 (1.1) 35.4 (27.0–40.9)
2015 5/2009 2276 1034 (45.4) 924 (40.6) 19.2 (14.3–27.4) 110 (4.8) 51.0 (39.9–59.2)
4/2010 2488 1216 (48.9) 1046 (42.0) 16.3 (14.0–23.5) 170 (6.8) 34.9 (24.6–50.4)
3/2011 2831 1443 (51.0) 1172 (41.4) 15.6 (13.5–21.9) 271 (9.6) 22.6 (17.2–30.4)
Varicella vaccination among cases reported to the DH
At least 1 dose 1st dose 2nd dose
Notification year Age
(years)
Number
reported
Number
received (%)
Number
received (%)
Median age (year) at 1st dose
(IQR)
Number
received (%)
Median age (month) at 2nd
dose (IQR)
20094 5 684 130 (19.0) 130 (19.0) 2.0 (1.0–3.0) – –
4 751 121 (16.1) 121 (16.1) 2.0 (1.0–2.0) – –
3 653 95 (14.5) 95 (14.5) 1.0 (1.0–2.0) – –
2012 5 861 177 (20.6) 147 (17.1) 1.0 (1.0–2.0) 6 (0.7) 3.0 (2.5–3.0)
4 951 182 (19.1) 146 (15.4) 2.0 (1.0–2.0) 7 (0.7) 3.0 (2.0–3.0)
3 727 126 (17.3) 105 (14.4) 1.0 (1.0–2.0) 3 (0.4) 1.0 (1.0–1.5)
2015 5 838 171 (20.4) 136 (16.2) 1.0 (1.0–2.0) 15 (1.8) 2.0 (2.0–5.0)
4 866 189 (21.8) 143 (16.5) 1.0 (1.0–2.0) 20 (2.3) 2.0 (1.0–2.0)
3 675 110 (16.3) 89 (13.2) 1.0 (1.0–1.3) 11 (1.6) 2.0 (1.0–2.0)
Note:
(1) Survey respondents and reported cases aged three to five were included in this study.
(2) Survey respondents and reported cases with missing vaccination information were not included in the above table. Those who were vaccinated with unknown
dose was not shown.
(3) Number and the proportion (%) of children received varicella vaccine for different doses was presented in the above table. Proportion was computed by the
number of children received the vaccine divided by the number surveyed/ reported in each stratum.
(4) Number of varicella vaccine received was not collected for cases reported in 2009. In view of low second-dose uptake for children surveyed in 2009, all vaccinated
varicella cases reported in 2009 were assumed to have received only one dose.
(5) Age of vaccination for survey respondents was computed by subtracting date of vaccination with date of birth. Median and interquartile range (IQR) of the age of
vaccination was presented in the above table to indicate timeliness of vaccination.
(6) Age of vaccination for varicella cases was collected by a standardized questionnaire for which the precision is up to year only.
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Rubin’s rules.14 We reported the pooled VE estimates alongside
their 95% confidence intervals in our results.
We computed the varicella VE of different doses (any, one
and two doses (for 2012 and 2015)) against different out-
comes including all varicella infections, varicella with compli-
cations, and varicella-related hospitalizations. In addition, we
included time since vaccination as a covariate in the logistic
regression model for VE against all varicella infections and
obtained the VE at different time periods since vaccination (0,
1, 2, 3, and 4 years) to assess whether there was evidence of
waning immunity.
Software
All analyses were done in R18 including the multiple imputation
via the MICE package.14
Ethical approval
Ethical approval was obtained from the Observational/
Interventions Research Ethics Committee of the London School
of Hygiene & Tropical Medicine as part of a modeling study of
varicella vaccination in Hong Kong (LSHTM ethics ref: 11852).
Results
Varicella vaccination uptake in the community
Uptake for at least one dose of varicella vaccine gradually
increased from about 25% for preschool children surveyed
in 2009 to about 50% for those surveyed in 2015 (Table 2).
Most preschool children only received one dose of varicella
vaccine. Second-dose vaccine uptake was about 1% or less in
2009 and 2012, and it increased to 5–10% in 2015. Age at
vaccination varied greatly among different cohorts, especially
for the second dose (Table 2).
Varicella notifications
A total of 7302 varicella cases aged 3–5 years were recorded in
2009, 2012, and 2015, corresponding to a notification rate of
1534 per 100,000. After excluding cases that were imported
(i.e. those who had a travel history during the incubation
period) (33), lived in residential care homes (4), and did not
attend preschools (259), we included 7006 cases in our ana-
lyses. Only two cases were immunosuppressed (one case of
nephritis and one case of pre-B acute lymphoblastic leuke-
mia). Twenty-nine cases (0.4%) had complications, among
which 18 were scarlet fever, one case each of pneumonia,
febrile convulsion, cellulitis and abscess due to methicillin-
resistant Staphylococcus aureus, and mild skin infection. Exact
complication type was not known for the remaining seven
cases. Seventy-five cases (1.1%) were admitted to hospitals but
no fatal case was identified.
The vaccination uptake for varicella cases slightly increased
from 16.6% in 2009 to 19.1% in 2012 and 19.8% in 2015
(Table 3). For cases reported in 2012 and 2015, less than 3% had
received a second dose (Table 2). The proportion of hospital
admissions was comparable for children of different vaccination
status albeit sample size was small (1.1% (95% CI 0.9–1.4) among
unvaccinated, compared to 1.0% (95% CI 0.6–1.8) and 1.6% (95%
CI 0.3–8.6) among one- and two-dose recipients). Among two-
dose recipients, there was no case with complication and only one
case was admitted to hospital.
Varicella VE
We estimated the VE of one-dose varicella vaccination against all
notified varicella as 69.4% (95%CI 67.5%–71.2). The respective
two-dose VE was substantially higher at 93.4% (95%CI 91.7–
94.7).We did not find evidence for waning immunity of varicella
vaccination against all notified varicella. For one-dose recipients,
the estimated VE did not decrease significantly with time since
receipt (Table 4). On the other hand, we found that two-dose VE
Table 3. Characteristics of varicella notifications aged 3–5 years1, Hong Kong, 2009, 2012, and 2015.
2009
(n = 2088)
2012
(n = 2539)
2015
(n = 2379)
Total
(n = 7006)
Characteristics N % N % N % N %
Female gender 923 44.2 1156 45.5 1063 44.7 3142 44.8
Age (years) 3 653 31.3 727 28.6 675 28.4 2055 29.3
4 751 36.0 951 37.5 866 36.4 2568 36.7
5 684 32.8 861 33.9 838 35.2 2383 34.0
Clinical condition Immunosuppression 0 0.0 1 0.0 1 0.0 2 0.0
Complications 3 0.1 13 0.5 13 0.5 29 0.4
Hospitalization 19 0.9 26 1.0 30 1.3 75 1.1
Varicella vaccination 346 16.6 485 19.1 470 19.8 1301 18.6
No. of dose
received2
1 NA NA 398 82.1 368 78.3 766 58.9
2 NA NA 16 3.3 46 9.8 62 4.8
Unknown 346 100.0 71 14.6 56 11.9 473 36.4
Age of last vaccination (year)2 <1 1 0.3 2 0.4 2 0.4 5 0.4
1 122 35.3 215 44.3 234 49.8 571 43.9
2 142 41.0 142 29.3 123 26.2 407 31.3
3 40 11.6 55 11.3 37 7.9 132 10.1
4 16 4.6 15 3.1 10 2.1 41 3.2
5 2 0.6 2 0.4 7 1.5 11 0.8
Unknown 23 6.6 54 11.1 57 12.1 134 10.3
Note:
1Two hundred and ninety-six cases were excluded from the analyses and thus not included in the above table (imported: 33, residential care homes: 4, did not attend
preschool: 259).
2Among those vaccinated with varicella vaccines.
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increased with time since receipt. Varicella vaccine was more
effective against complications: 85.4% (95%CI 48.8–95.8) for one
dose and 100% (95%CI –Inf to 100) for two doses. The effective-
ness of varicella vaccines against hospital admission was 75.2%
(95% CI 53.4–86.8) and 93.1% (95% CI 47.1–99.1) for one- and
two-dose recipients, respectively (Table 4).
Discussion
We used the screening method to estimate the varicella VE
among preschool children in Hong Kong. We showed that
one-dose varicella vaccination conferred moderate direct pro-
tection [69.4% (95% CI 67.5–71.2)] against notified varicella
whilst two doses conferred strong direct protection [93.4%
(95% CI 91.7–94.7)]. VE against complications and hospital
admissions was also generally higher for those who received
two doses, though numbers were too small to conclude of
superiority. We did not find any evidence to support concerns
that vaccine protection from one dose would wane before
children entering primary school.
Our VE estimates are largely comparable to a recent meta-
analysis of post-licensure VE studies6 which also showed that one-
dose varicella vaccine (mostly mVV) is moderately effective for
preventing disease of any severity [81% (95% CI 78–84%)] but
two-dose varicella vaccine is highly effective at 98% (95% CI 97–
99%). We also found that the effect of varicella vaccination per-
sisted in the first few years after vaccination with no apparent
decline in VE. For two-dose vaccinees, there was a general trend of
increasing effectiveness with time since vaccine receipt. There are
a few possible explanations behind this observation. First, as
children aged, they had more exposure to circulating wild-type
varicella, whichmight boost up their immunity. Second, vaccinees
who failed to develop adequate immunity would be infected and
became immune to further varicella infections. Thus, the number
of vaccinated yet susceptible children would decrease with time
and contribute less to the varicella reported in later years. This
would result in lower PCV and higher VE in later years. Third,
there were only 62 reported cases having received two doses of
varicella vaccine and the estimation of two-dose VE by year since
vaccination was more prone to error due to small sample size.
Clinical trials of Varivax showed that vaccinees who were initially
protected lost their protection rather quickly,19 while some studies
showed that antibodies against varicella were persistent among
vaccinees after 10- to 20-year follow-up, though boosting by
circulating wild-type VZV cannot be ruled out.20 Systematic
review found that waning immunity for single-dose vaccination
was not conclusive,20,21 and long-term protection of up to 14 years
had been demonstrated for two-dose regimen in the World
Health Organization’s systematic review.22
As one-dose varicella vaccine induces only moderate pro-
tection, breakthrough infections are often observed in one-
dose vaccinees.4,5 Although waning immunity after first dose
varicella vaccination remains inconclusive, the lower VE is
generally believed to be a result of primary vaccine failure
which mainly occurred after first dose, as evidenced by only
76–84% of one-dose recipients seroconverted (assessed by
fluorescent antibody to membrane antigen test, the most
specific laboratory test for serological correlates of varicella
infection and vaccination).21 Furthermore, IgG geometric
mean concentration of subjects receiving the first dose
MMRV of MSD (ProQuad) was lowest for varicella and the
boosting effect after the second dose was much more pro-
found for varicella,3 suggesting that immune response fol-
lowing only one dose against varicella is likely incomplete. In
addition to nonconverter (primary vaccine failure), mild
breakthrough infections occurring among seroconverted
vaccinees (commonly defined as those who had >5 glyco-
protein enzyme-linked immunosorbent assay units/mL) may
be a result of partial or “leaky” protection.4,21 Thus, second-
dose varicella vaccination is important in completing the
incomplete immune response following first-dose vaccina-
tion and maximizing the impact of varicella vaccination.
After the start of a one-dose program in 1995, the United
States switched to a two-dose regimen in 2006 as varicella
outbreaks persisted even among the highly vaccinated parts
of the population.23 Providing second-dose vaccination at
4–6 years of age led to further declines in varicella incidence,
hospitalizations, and outbreaks in the US.24 It should be
noted that, however, more than half of the 29 countries or
areas with funded varicella vaccination adopt a one-dose
schedule and most of those with two-dose vaccination have
a second dose scheduled at ≥4 years [Information summar-
ized from WHO, European Center for Disease Control, MSD
and GSK].
Table 4. Vaccine effectiveness for different doses of varicella vaccine against all
varicella, varicella with complications, and varicella admissions among preschool
children aged 3–5 years in Hong Kong.
Outcome/dose Vaccine effectiveness % (95% CI)
All varicella
Any dose 68.7 (66.8–70.5)
Time since vaccination (year) 0 68.7 (63.4–73.3)
1 68.7 (61.1–74.8)
2 68.7 (58.7–76.3)
3 68.7 (56.1–77.7)
4 68.7 (53.3–79.0)
1 dose 69.4 (67.5–71.2)
Time since vaccination (year) 0 70.8 (65.7–75.2)
1 70.2 (62.8–76.2)
2 69.7 (59.8–77.3)
3 69.2 (56.4–78.3)
4 68.7 (52.8–79.2)
2 doses 93.4 (91.7–94.7)
Time since vaccination (year) 0 86.4 (77.2–92.0)
1 90.6 (80.0–95.6)
2 93.5 (82.5–97.6)
3 95.5 (84.7–98.7)
4 96.9 (86.6–99.3)
Complication
Any dose 86.0 (50.9–96.0)
1 dose 85.4 (48.8–95.8)
2 doses 100.0 (–Inf to 100.0)
Hospital admission
Any dose 74.2 (52.6–86.0)
1 dose 75.2 (53.4–86.8)
2 doses 93.1 (47.1–99.1)
Note:
• Time since vaccination was included as a covariate only in the logistic regres-
sion model for VE against all varicella infections.
• Since dose of vaccine received was not collected for varicella cases reported in
2009 and the second-dose varicella vaccination uptake in the population is
very low, all vaccinated cases reported in 2009 were assumed to have only
received one dose of vaccine. As such, VE estimation for any dose (ever
vaccinated) and one dose was based on all 3 study years (2009, 2012, and
2015) whereas two doses was based on data from 2012 and 2015 only.
• Variable “dose no.” was not added in the regression model when estimating VE
for any dose due to issue in model convergence. As such, VE for any dose was
not adjusted for no. of doses received.
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In Hong Kong, the implementation of UVV has rapidly
increased the first dose varicella vaccination uptake to about
99% for eligible preschool children.10 Reduction in varicella noti-
fication was observed shortly after universal vaccination, as the
annual notification rate per 100,000 among children aged 3–5 had
decreased from 1670 to 2916 between 2011 and 2013 and to
934–1256 between 2015 and 2018 (Supplementary Figure 3).
Preschool outbreaks also decreased to a lower level but persisted
in recent years (292–442 outbreaks annually from 2011 to 2013
compared with 111–284 outbreaks annually from 2015 to 2018).
The Scientific Committee on Vaccine Preventable Diseases, the
advisory body on immunization in Hong Kong, recently recom-
mended advancing second-dose vaccines against measles,
mumps, rubella, and varicella (given as combined MMRV) from
Primary One to 18months of age.25 Given the higher effectiveness
of second-dose vaccination, this change in the program should
reduce breakthrough infection and accumulation of susceptible
children who experienced primary vaccine failure, and it would
further limit varicella transmission and outbreaks in preschools.
In addition, herpes zoster appeared to be less common among
children vaccinated against varicella.26,27 Therefore, advancing
the second-dose vaccine to 18 months of age should also bring
a long-term impact of decreasing the probability of vaccinated
children developing zoster later in their life.
We previously reported the burden of varicella having shifted
to older children before UVV.2 The epidemiology of varicella
and zoster is expected to change further as high varicella vacci-
nation uptake has been achieved for children eligible for UVV.
To assess the potential long-term impact of UVV on varicella
and zoster, as well as different options to maximize the benefits
of the vaccination program, we will model the transmission of
VZVmechanistically. These local VE estimates provided impor-
tant baseline data to monitor the impact of the UVV and could
serve as important inputs for the mathematical model.
There were some limitations to this study. First, most varicella
cases were ascertained clinically without laboratory confirmation.
Breakthrough varicella with modified (less severe) symptoms is
more difficult to be diagnosed clinically and is expected to increase
with higher vaccination uptake. Inclusion of non-varicella cases
will underestimate the VE. Second, varicella is generally
a nonsevere disease and underreporting exists. We previously
estimated that less than 50% of varicella infections were notified
among those aged 3–5 years and the reporting sensitivity varied
with time and age.2 This may bias our VE in different directions,
depending on whether vaccinated cases are more likely to be
reported. For instance, those who chose to actively vaccinate
might be more aware of varicella and hence more likely to seek
medical consultation and be reported. This would bias our VE
estimates toward null. On the other hand, breakthrough varicella
cases with milder symptoms may be less likely to seek medical
consultation or require hospital admission. This will underesti-
mate PCV and overestimate the VE. To our knowledge, we are
not aware of reports on how varicella vaccination affects health-
seeking and reporting behavior, though severe varicella in vacci-
nated children are rare.28 Third, complication and hospitalization
alonemight not be representative of clinical severity, as we did not
collect further details such as the number of vesicles developed
and the duration of hospitalization. Young children with varicella
might be hospitalized for fever work-up instead of clinical severity.
This would lead to underestimation of VE against admissions.
Our VE estimates against complications were higher than that
against hospital admissions. Varicella vaccine was shown to be
more effective against severe outcomes, but severe disease in some
observational studies was defined as varicella with ≥500 lesions or
presence of complications/hospitalization.6,22 It should be noted
that the median interval between interview and disease onset was
only 3 days (interquartile range: 2–8 days) for cases included in
our study. Cases that developed complications or hospitalized
after data collection would not be counted as severe cases.
Fourth, although adequate immunity against clinical disease
might not have developed until 1 month after vaccination,3
cases that developed disease shortly after vaccination would still
be regarded as vaccinated as the exact date of vaccination was not
available for most varicella notifications. This will overestimate
the PCV and underestimate the VE. Fifth, information on the
exact vaccine product received by varicella cases was not collected
and we were unable to estimate VE specific to different formula-
tions. As children received varicella vaccines from different man-
ufacturers (Table 1), our VE estimates were the effect of mixed
vaccine products. Nevertheless, with the exception of varicella
vaccine manufactured in South Korea, varicella vaccines available
in Hong Kong are based on the Oka strain and their effectiveness
are generally comparable.6 Sixth, ascertainment of vaccination
status was different for the survey and notification. Vaccination
status for surveyed children was ascertained by reviewing medical
records, while that for most varicella notification was ascertained
by parental recall. Thus, vaccination status of varicella cases was
more prone to recall bias and it might affect the accuracy of PCV.
Conclusion
Weshowed that varicella vaccine is effective in preventing varicella
infection, complication, and hospitalization in Hong Kong, espe-
cially for two-dose vaccination. Countries with UVV should con-
sider adopting a two-dose strategy with a short interval between
the first and second doses to reduce breakthrough varicella and
outbreaks in preschool. In view of the high VE, the epidemiology
of varicella and herpes zoster is expected to change as universal
vaccination program successfully rolls out in Hong Kong.
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